This is a preview of subscription content, log in via an institution to check access.
Data availability
Data are available on request from the author (JLM).
References
Free RB, Clark J, Amara S, Sibley DR (2018) Neurotransmission in the central nervous system. In Goodman and Gilman’s the pharmacological basis of therapeutics. Eds LL. Brunton, R. Hilal-Dandan, BJ. Knollmann. Mc Graw Hill New York 13th edition. 243–65
Romigi A, Vitrani G, Lo Giudice T, Centonze D, Franco V (2018) Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. Drug Des Devel Ther 12:2665–2675
Lamb YN (2020) Pitolisant: a review in narcolepsy with or without cataplexy. CNS Drugs 34:207–218
Sarfaz N, Okuampa D, Hansen H, Alvarez M, Cornett EM, Kakazu J, Kaye AM, Kaye AD (2022) pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Health Psychol Res 34222
Montastruc JL (2022) Pharmacovigilance and drug safety: fair prescribing and clinical research. Therapie 77:261–263
Bihan K, Lebrun-Vignes B, Funck-Brentano C, Salem JE (2020) Uses of pharmacovigilance databases : an overview. Therapie 75:591–598
Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905–908
Faillie J-L (2019) Case-non case studies: principles, methods, bias and interpretation. Therapie 74:225–232
Ligneau X, Shah RR, Berrebi-Bertrand I, Mirams GR, Robert P, Landais L, Maison-Blanche P, Faivre JF, Lecomte JM, Schwartz JC (2017) Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies. Br J Pharmacol 174:4449–4463
Acknowledgements
The author acknowledges the Uppsala Monitoring Centre, which provided and gave permission to use the data analyzed in the present study. He also is indebted to the National Pharmacovigilance Centers that contributed data. The opinions and conclusions in this study are not necessarily those of the various centers or of the WHO or Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), France.
Author information
Authors and Affiliations
Contributions
JLM designed the study, extracted the data from the database, performed the analysis, and wrote the paper.
Corresponding author
Ethics declarations
Competing interests
JLM declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Montastruc, JL. Safety of pitolisant: a study in the WHO international pharmacovigilance database. Eur J Clin Pharmacol 79, 569–570 (2023). https://doi.org/10.1007/s00228-023-03460-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-023-03460-0